|
|
Enter your search term above and find:
· CAS Numbers
· Molecular Formulas
· Synonyms
· Sites/Web Search
· Suppliers
· Resources
|
|
|
|
|
|
|
|
|
|
|
Synonyms:
[fewer]
1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]proline, (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenyl-propyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid, (2S)-1-[(2S)-6-amino-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid, (2S)-1-[(2S)-6-azanyl-2-[[(2S)-1-hydroxy-1-oxo-4-phenyl-butan-2-yl]amino]hexanoyl]pyrrolidine-2-carboxylic acid, 76547-98-3, 77726-95-5, 83915-83-7, Acerbon, Acercomp, Alapril, BB_NC-1454, BPBio1_000290, BRN 4276619, BSPBio_000262, C21H31N3O5, Carace, CCRIS 3568, CHEBI:43755, Cipral, Cipril, Coric, DB00722, DivK1c_001037, Doneka, EINECS 278-488-1, ICI-209K, IDI1_001037, Inhibril, Inopril, KBio1_001037, KBio2_000977, KBio2_003545, KBio2_006113, KBio3_002002, KBioGR_001599, KBioSS_000977, Linopril, Linvas, Lipril, Lisinal, lisinopril, Lisinopril anhydrous, Lisinopril (anhydrous), Lisinoprilum [Latin], Lisipril, Lisoril, Lispril, Longes, Loril, LPR, L-Proline, 1-(N2-(1-carboxy-3-phenylpropyl)-L-lysyl)-, L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, L-Proline, 1-(N(sup 2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-, (S)-, L-Proline, N2-((1S)-1-carboxy-3-phenylpropyl)-L-lysyl-, LS-118899, Lysinopril, MK 521, MK-521, MK 522, MLS001306481, N-(1(S)-Carboxy-3-phenylpropyl)-L-lysyl-L-proline, N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline, N2-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline, N2-((S)-1-Carboxy-3-phenylpropyl)-L-lysyl-L-proline, [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE, NCGC00179623-01, NINDS_001037, Noperten, Novatec, parent cpd, Presiten, Prestwick0_000301, Prestwick1_000301, Prestwick2_000301, Prestwick3_000301, Prinil, Prinivil, (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline, (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, (S)-1-(N(sup 2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, Sinopril, Sinopryl, SMR000544473, SPBio_001351, SPBio_002481, Spectrum_000497, SPECTRUM1501217, Spectrum2_001456, Spectrum3_000941, Spectrum4_001040, Spectrum5_000995, Tensopril, Tensyn, Tersif, TL8005499, Vivatec, Zestril
|
|
|
|
|
|
|
|
|
|
|
Featured suppliers/resources for
MK 521
|
|
|
|
|
|
|
Taizhou Crene Biotechnology Co., Ltd. |
Manufacturer |
China |
The company cooperate with R & D centers in famous university and GMP manufacture plants. we carry out scientific management. Company provides one-stop services of research - development - production for a variety of special prouducts.
URL: http://www.pharm-intermediates.com in English [Translate]
|
|
 |
|
Hangzhou DayangChem Co., Ltd. |
Manufacturer |
China |
The company dedicated to the development, production and marketing of chemicals. Focus on:Organic compounds,Active Pharmaceutical Ingredient(s),Nutritional products,Custom synthesis and Contract Manufacturing.
URL: http://www.chinadayangchem.com/ in English [Translate]
|
|
|
|
Hangzhou J&H Chemical Co.,LTD |
Manufacturer |
China |
Pls send your inquiry to sales@jhechem.com. Hangzhou J&H Chemical Co., LTD specialize in producing, offering and developing a wide range of chemicals.We welcome you to contact us and look forward to becoming your reliable partner.
URL: http://www.jhechem.com in English [Translate]
|
|
|
|
Finipharma Ltd |
Manufacturer |
China |
Inquiry Emal:info@finipharma.com
FINIPHARMA LIMITED is a specialized API&chemical supplier for research, development and production.
FINIPHARMA LIMITED is one of the leading suppliers in the API,intermediate and chemical industry.
URL: http://www.finipharma.com in English [Translate]
|
|
|
 |
|
Hangzhou Royall Import & Export Co.,Ltd. |
Manufacturer |
China |
JINLAN PHARMA(Hangzhou Royall Import & Export Co.,Ltd.) is mainly engaged in R&D, manufacturing and marketing pharmaceuticals, chemical intermediates, Biochemicals, Veterinary medicines and Nutrition products.
URL: http://www.royalpharms.com in English [Translate]
|
|
|
|
|
|
|
|
|
|
|
